Payment overview · 2025
General Payments
$1,331.56
72 reported records · 19 companies
Healthcare provider profile · identity verified
Harold J Pean, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MISSION, TX · NPI 1013950484
Verified facts
What the public records show
CMS Open Payments records show Harold J Pean, MD received $1,331.56 in general payments during 2025 across 72 reported records.
Novo Nordisk Inc accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Qulipta, Rexulti, Rybelsus, Trelegy Ellipta, Verquvo, Vraylar, Xifaxan, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 417 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 427 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $200.75 | 15.1% | 14 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $192.16 | 14.4% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $168.80 | 12.7% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $115.93 | 8.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $100.63 | 7.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.68 | 5.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $69.19 | 5.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.24 | 5.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $61.71 | 4.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $52.79 | 4.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.94 | 3.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.90 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.63 | 2.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.84 | 2.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.21 | 2.2% | 2 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $20.77 | 1.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.25 | 1.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.73 | 1.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.41 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,331.56 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $119.45 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $115.93 | 4 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $107.75 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $107.75 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $103.63 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $100.63 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $84.41 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $79.74 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $76.80 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.93 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $69.19 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $61.71 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.71 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $52.79 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.28 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.28 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.50 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.14 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.94 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.90 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.84 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $29.54 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.21 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.89 | 3 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 223 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 417 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 277 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 166 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 292 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 427 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 166 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 218 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 48 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 47 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
166 | 41 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
62 | 41 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
175 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
417 | 95 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
75 | 74 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
60 | 52 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
218 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
277 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
292 | 34 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
427 | 65 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
166 | 25 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
223 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 806 | 239 |
| Levothyroxine Sodium | Levothyroxine Sodium | 613 | 158 |
| Metformin Hcl | Metformin Hcl | 439 | 121 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 427 | 50 |
| Ozempic | Semaglutide | 427 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 418 | 139 |
| Farxiga | Dapagliflozin Propanediol | 417 | 95 |
| Diclofenac Sodium | Diclofenac Sodium | 377 | 109 |
| Losartan Potassium | Losartan Potassium | 340 | 105 |
| Furosemide | Furosemide | 336 | 86 |
| Gabapentin | Gabapentin | 336 | 106 |
| Lisinopril | Lisinopril | 320 | 93 |
| Mounjaro | Tirzepatide | 292 | 34 |
| Jardiance | Empagliflozin | 277 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 92 |
| Omeprazole | Omeprazole | 275 | 86 |
| Meloxicam | Meloxicam | 274 | 108 |
| Eliquis | Apixaban | 223 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 218 | 41 |
| Baclofen | Baclofen | 208 | 62 |
| Montelukast Sodium | Montelukast Sodium | 202 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 63 |
| Memantine Hcl | Memantine Hcl | 197 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 60 |
| Alprazolam | Alprazolam | 179 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 61 |
| Myrbetriq | Mirabegron | 175 | 41 |
| Buspirone Hcl | Buspirone Hcl | 170 | 42 |
| Linzess | Linaclotide | 166 | 41 |
| Rybelsus | Semaglutide | 166 | 25 |
| Tramadol Hcl | Tramadol Hcl | 161 | 50 |
| Vascepa | Icosapent Ethyl | 147 | 27 |
| Meclizine Hcl | Meclizine Hcl | 142 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 20 |
| Sertraline Hcl | Sertraline Hcl | 139 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 128 | 51 |
| Xarelto | Rivaroxaban | 127 | 36 |
| Azelastine Hcl | Azelastine Hcl | 123 | 58 |
| Potassium Chloride | Potassium Chloride | 123 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 122 | 86 |
| Lorazepam | Lorazepam | 116 | 23 |
| Famotidine | Famotidine | 115 | 41 |
| Alendronate Sodium | Alendronate Sodium | 114 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 37 |
| Spironolactone | Spironolactone | 105 | 33 |
| Ezetimibe | Ezetimibe | 104 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 29 |
| Propranolol Hcl | Propranolol Hcl | 104 | 33 |
| Cilostazol | Cilostazol | 103 | 30 |
| Fenofibrate | Fenofibrate | 103 | 28 |
| Mupirocin | Mupirocin | 102 | 54 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 29 |
| Azithromycin | Azithromycin | 101 | 80 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 96 | 57 |
| Trintellix | Vortioxetine Hydrobromide | 96 | 25 |
| Trazodone Hcl | Trazodone Hcl | 93 | 22 |
| Allopurinol | Allopurinol | 92 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 88 | 29 |
| Glimepiride | Glimepiride | 87 | 23 |
| Ursodiol | Ursodiol | 86 | 23 |
| Carvedilol | Carvedilol | 82 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 30 |
| Ibuprofen | Ibuprofen | 82 | 29 |
| Simvastatin | Simvastatin | 82 | 22 |
| Entresto | Sacubitril/Valsartan | 81 | 18 |
| Januvia | Sitagliptin Phosphate | 81 | 21 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 75 | 74 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 15 |
| Megestrol Acetate | Megestrol Acetate | 71 | 20 |
| Terbinafine Hcl | Terbinafine Hcl | 70 | 35 |
| Gemtesa | Vibegron | 68 | 26 |
| Pentoxifylline | Pentoxifylline | 67 | 24 |
| Tresiba Flextouch U-200 | Insulin Degludec | 67 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 63 | 22 |
| Mirtazapine | Mirtazapine | 62 | 12 |
| Prednisone | Prednisone | 62 | 34 |
| Prolia | Denosumab | 62 | 41 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 60 | 52 |
| Tradjenta | Linagliptin | 60 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 60 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 59 | 25 |
| Belsomra | Suvorexant | 58 | 16 |
| Cephalexin | Cephalexin | 58 | 41 |
| Clonazepam | Clonazepam | 56 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 13 |
| Fluconazole | Fluconazole | 53 | 36 |
| Glipizide | Glipizide | 51 | 17 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 51 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 16 |
| Ammonium Lactate | Ammonium Lactate | 50 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 26 |
| Memantine Hcl Er | Memantine Hcl | 49 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 12 |
| Verquvo | Vericiguat | 48 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 32 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 47 | 15 |
| Xifaxan | Rifaximin | 47 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 45 | 16 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 45 | 31 |
| Acetic Acid | Acetic Acid | 44 | 25 |
| Dutasteride | Dutasteride | 43 | suppressed |
| Primidone | Primidone | 43 | 15 |
| Dapagliflozin | Dapagliflozin Propanediol | 42 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 14 |
| Nystatin | Nystatin | 42 | 19 |
| Pregabalin | Pregabalin | 42 | 14 |
| Finasteride | Finasteride | 41 | 14 |
| Ranolazine Er | Ranolazine | 39 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 38 | 13 |
| Chlorthalidone | Chlorthalidone | 37 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 11 |
| Lactulose | Lactulose | 34 | 11 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Mupirocin | Mupirocin Calcium | 34 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 24 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 14 |
| Midodrine Hcl | Midodrine Hcl | 29 | 13 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | suppressed |
| Repatha Syringe | Evolocumab | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | 11 |
| Zenpep | Lipase/Protease/Amylase | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 14 |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 23 | 17 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Livalo | Pitavastatin Calcium | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Nexletol | Bempedoic Acid | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 21 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 20 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Trulance | Plecanatide | 20 | suppressed |
| Qulipta | Atogepant | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Erythromycin | Erythromycin Base | 18 | 13 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 17 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,331.56 · 72 records | Novo Nordisk Inc | Auvelity, CAPLYTA, CREON, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, ImmunoCAP, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZENPEP, ZEPBOUND | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error